HAI Book 2025 - Flipbook - Page 7
70 Whole-blood gene expression
associations with A´-PET accumulation
and cognitive decline .......................... 335
80 Predicting regional Alzheimer9s disease
pathology with plasma p-tau217 in
preclinical AD ......................................363
Bilgel, Murat ....................................... 338
Pascual, Belen.................................... 366
71 Longitudinal change in ove dominant
dimensions of brain aging in relation to
brain amyloid status and Alzheimer9srelated plasma biomarkers .................. 338
81 TSPO-PET before and after low-dose
interleukin-2 in patients with mild to
moderate Alzheimer's disease ..............366
Mundada, Nidhi ................................... 341
72 Enrichment of patients with
concomitant LATE on the Alzheimer9s
disease continuum using hippocampal
volume................................................. 341
Lopresti, Brian ................................... 345
Hanseeuw, Bernard............................ 367
82 In low neocortical tau individuals, high
amygdala tau predicts faster cognitive
decline ................................................ 367
Katsumi, Yuta..................................... 370
83 EOAD-signature atrophy predicts
progression to dementia in patients with
early-onset MCI due to Alzheimer9s disease
...........................................................370
73 AT(N) staging of Alzheimer9s disease:
Comparison of visual interpretation and
automated quantiocation pipelines ..... 345
McLachlan, Max................................... 371
74 MK-6240 off-target binding patterns in
relation to microglia density, measured
through TSPO PET............................... 347
84 FDG reference region selection using
PiB amyloid status-guided iterative
normalization in a Down syndrome cohort
........................................................... 371
Heuer, Lauren .................................... 347
Mroué, Rayan...................................... 349
Kunach, Peter .................................... 374
75 Association between medication use
and [18F]MK6240 and [18F]Flortaucipir
uptake across the Alzheimer's disease
spectrum ............................................ 349
85 Microscopic visualization of
nuorescent MK-6240 ...........................374
Koops, Elouise ................................... 352
76 Lower LC-EC tract integrity is
associated with entorhinal tau in
autosomal-dominant Alzheimer9s disease
........................................................... 352
McVea, Andrew .................................. 355
77 APOE4 associated with higher offtarget meninges signal with [F-18]MK6240
PET .................................................... 355
Minhas, Davneet................................. 358
78 An accurate and automated technique
for removing spill-over contamination and
off-target retention from a cerebellar
reference region for tau PET ................ 358
Schwarz, Christopher ........................ 362
79 Updated public CenTauR pipelines to
measure CenTauR, CenTauRZ, and SUVR
tau PET units ...................................... 362
Moon, Hasom...................................... 363
HAI2025 - 7
Leuzy, Antoine ................................... 375
86 Conversion of Tau PET SUVR data to
CenTauR units using the Joint Propagation
Model .................................................. 375
Liu, Peiwei .......................................... 378
87 The role of cohort heterogeneity in
predicting AD/ADRD cognitive decline .. 378
Khurelbaatar, Bayarjargal .................. 379
88 Differential tau accumulation in earlyonset and late-onset Alzheimer's disease:
Insights from [18F]-Florzolotau PET ..... 379
Silva-Rodríguez, Jesús ....................... 381
89 Heterogeneity of FDG-PET patterns
among tau-negative amnestic patients 381
Huang, Shao-Yi .................................. 383
90 Predicting amyloid positivity and tau
burden in dementia using a combination of
different biomarkers ............................383
Kulagowska, Laura............................. 385
91 Evaluation of [³H]SynVesT - 1 binding in
post-mortem brain tissue from control and
